(Q47678083)

4 February 2018

title

Two HBV DNA+/HBsAg- blood donors identified by HBV NAT in Shenzhen, China (English)

1 reference

4 February 2018

author

Clive R. Seed

7

1 reference

4 February 2018

author name string

Guifang Shang

1

1 reference

4 February 2018

Youqing Yan

2

1 reference

4 February 2018

Baocheng Yang

3

1 reference

4 February 2018

Chaopeng Shao

4

1 reference

4 February 2018

Fei Wang

5

1 reference

4 February 2018

Qian Li

6

1 reference

4 February 2018

publication date

31 May 2009

1 reference

4 February 2018

Transfusion and Apheresis Science

published in

1 reference

4 February 2018

volume

41

1 reference

4 February 2018

issue

1

1 reference

4 February 2018

page(s)

3-7

1 reference

4 February 2018

Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

A multi-Chinese blood center study testing serologic-negative donor samples for hepatitis C virus and human immunodeficiency virus with nucleic acid testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

Occult hepatitis B virus infection and its clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

High prevalence of occult hepatitis B in Baltimore injection drug users

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

Hepatitis B virus genotypes, phylogeny and occult infection in a region with a high incidence of hepatocellular carcinoma in China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

Occult hepatitis B viral DNA in liver carcinomas from a region with a low prevalence of chronic hepatitis B infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

Long-term clinical impact of occult hepatitis B virus infection in chronic hepatitis B patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

Occult hepatitis B virus infection in a North American adult hemodialysis patient population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

Occult hepatitis B virus infection in HBs antigen-negative hepatocellular carcinoma in a Japanese population: involvement of HBx and p53.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

Value of anti-HBc screening of blood donors for prevention of HBV infection: results of a 3-year prospective study in Northwestern Greece

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

Hepatitis B virus DNA in sera of virus carriers positive exclusively for antibodies to the hepatitis B core antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

Approximate Is Better than "Exact" for Interval Estimation of Binomial Proportions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

Hepatitis B - a review of the role of NAT in enhancing blood safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

Comparison of two automated nucleic acid testing systems for simultaneous detection of human immunodeficiency virus and hepatitis C virus RNA and hepatitis B virus DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

Lengths of hepatitis B viremia and antigenemia in blood donors: preliminary evidence of occult (hepatitis B surface antigen-negative) infection in the acute stage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

HBV: amplified and back in the blood safety spotlight

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

Pooled hepatitis B virus DNA testing by nucleic acid amplification: implementation or not.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

Occult hepatitis B infection in blood donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

Individual nucleic amplification technology does not prevent all hepatitis B virus transmission by blood transfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2009.05.001

10.1016/J.TRANSCI.2009.05.001

7 January 2021

Identifiers

DOI

1 reference

4 February 2018

PubMed ID

19487161

1 reference

4 February 2018